India Pharma Outlook Team | Tuesday, 30 June 2026
Aurobindo Pharma's Lannett Acquisition has officially entered a new phase with the successful completion of its USD 250 million buyout of US-based Lannett Company.
The deal, which was first announced in July 2025, has now crossed the final regulatory hurdle after receiving FTC approval, marking a major milestone in Aurobindo's expansion in the US pharmaceutical market.
The Acquisition strengthens the company's manufacturing footprint, broadens its generic drugs portfolio, and supports its long-term growth strategy in the United States.
The acquisition was completed through the company's wholly owned subsidiary, Aurobindo Pharma USA Inc. (APUSA), on June 29, 2026. Following the completion of the transaction, Lannett Company, Inc. has been converted into Lannett Company LLC, which will continue to operate as a wholly owned subsidiary of APUSA.
The acquisition journey began in July 2025, when Aurobindo Pharma announced plans to acquire Lannett for approximately USD 250 million on a cash-free, debt-free basis. The move was aimed at strengthening the company's position in the US pharmaceutical industry by adding domestic manufacturing capacity and expanding its portfolio of complex generic medicines.
Before the transaction could be completed, it required approval from the US Federal Trade Commission (FTC). Earlier this month, the regulator cleared the acquisition after Aurobindo agreed to divest four generic drug products to address competition concerns. With the regulatory process completed, the company officially closed the deal on June 29.
Also Read: Driving Vaccine Adoption Beyond Pediatric Immunization in India
The acquisition gives Aurobindo Pharma a stronger manufacturing base in the United States through Lannett's facility in Seymour, Indiana. The site has the capacity to manufacture nearly 4 billion doses annually, significantly increasing the company's domestic production capabilities.
The deal also brings more than 400 Lannett employees into Aurobindo's workforce, adding experienced talent across manufacturing and operations.
Apart from expanding production capacity, the acquisition strengthens Aurobindo's portfolio of generic drugs, particularly complex products, including non-opioid controlled substances. It also enhances the company's CDMO (Contract Development and Manufacturing Organization) capabilities, allowing it to support both internal manufacturing and contract production for other pharmaceutical companies.
The completion of Aurobindo Pharma's Lannett Acquisition marks a key step in the company's long-term strategy to expand its footprint in the US pharmaceutical market. By combining Lannett's manufacturing infrastructure with Aurobindo's existing operations, the company expects to improve supply chain resilience, increase local production, and strengthen its ability to serve customers across the United States.
The acquisition is also expected to contribute to earnings from the first year of integration, while operational efficiencies and cost synergies are likely to support future growth.
With regulatory approvals secured, additional manufacturing capacity in place, and a broader product portfolio, Aurobindo Pharma has completed one of its most significant overseas acquisitions. The successful integration of Lannett is expected to strengthen the company's position in the competitive US generic drug market and create new opportunities for sustainable growth in the years ahead.
Aurobindo Pharma is one of India’s leading pharmaceutical companies with a strong presence in generic medicines, active pharmaceutical ingredients (APIs), and specialty products. The company operates across more than 150 countries and has a significant footprint in the US and European markets.
Lannett is a US-based pharmaceutical manufacturer known for producing and distributing generic pharmaceutical products. The company has built a diversified portfolio across multiple therapeutic categories and operates manufacturing facilities serving the US healthcare market.
.jpg)
